High or increasing serum NfL is predictive of impending multiple sclerosis relapses
Source : https://www.msard-journal.com/article/S2211-0348(22)00050-5/fulltext
With an expanding spectrum of disease-modifying treatments (DMTs) for patients with MS, the need for biomarkers that can identify patients at risk of impending disease activity who might benefit from pro-active treatment optimization has never been more urgent.
Conclusion: We enumerate the risk of relapse associated with dynamic changes in sNfL. Both baseline and longitudinal change in sNfL may help identify patients who would benefit from early treatment optimisation.